Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)

Title
Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
Authors
Keywords
Glycaemic control, Glucagon-like peptide-1 receptor agonist, Liraglutide, Semaglutide, Type 2 diabetes, SUSTAIN
Journal
DIABETES & METABOLISM
Volume -, Issue -, Pages 101117
Publisher
Elsevier BV
Online
2019-09-17
DOI
10.1016/j.diabet.2019.101117

Ask authors/readers for more resources

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started